Bispecific Or Bifunctional, Or Multispecific Or Multifunctional, Antibody Or Fragment Thereof Patents (Class 424/136.1)
  • ANTI-CLTA4, ANTI-GLUT2 PROTEIN FOR THE TREATMENT OF TYPE 1 DIABETES
    Publication number: 20130323250
    Abstract: The disclosure relates to a protein composed of a first polypeptide or polypeptide domain having a first specific binding activity for Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) expressed on a T-cell cell surface and a second specific binding activity for Glucose Transporter 2 (GLUT2) or an extracellular ectodomain thereof expressed on a pancreatic ?-cell surface, wherein binding of the first polypeptide or polypeptide domain to CTLA-4 induces a CTLA-4 specific agonist response in the T-cell, and binding of the second polypeptide or polypeptide domain to GLUT2 or an ectodomain thereof does not inhibit GLUT2 glucose transporter function, wherein said agonist response in the T-cell induces a response that reduces immunoreactivity against pancreatic ?-cells.
    Type: Application
    Filed: July 17, 2013
    Publication date: December 5, 2013
    Inventors: Bellur S. PRABHAKAR, Chenthamarakshan VASU, Palash BHATTACHARYA
  • ANTIBODIES TO TUMOR ENDOTHELIAL MARKER 8
    Publication number: 20130323173
    Abstract: The present invention is directed to particular antibodies and fragments thereof that find use in the detection, prevention and treatment of diseases and disorders associated with abnormal angiogenesis. In particular, these antibodies detect tumor endothelial marker 8 (TEM8) in its native and cell-surface expressed form. Also disclosed are improved methods for producing monoclonal antibodies, as well as pharmaceutical compositions and kits.
    Type: Application
    Filed: November 14, 2011
    Publication date: December 5, 2013
    Applicant: The Government of the United States of America, as Represented by the Secretary, Department of Healt
    Inventors: Arthur E. Frankel, Yuripeng Su, Brad St. Croix
  • USE OF MDL-1 ANTAGONISTS TO TREAT SPONDYLARTHROPATHY
    Publication number: 20130323246
    Abstract: The invention provides methods for treating spondylarthropathy with antagonists of MDL-1 alone or in combination with IL-23 antagonists.
    Type: Application
    Filed: February 14, 2012
    Publication date: December 5, 2013
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Daniel J. Cua, Barbara Joyce-Shaikh, Drake LaFace, Jonathan P. Sherlock
  • Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
    Patent number: 8598321
    Abstract: This invention provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: December 3, 2013
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Isin N. Geren, Jianlong Lou
  • Fusion polypeptides capable of activating receptors
    Patent number: 8597898
    Abstract: A fusion polypeptide comprising (A)x-M-(A?)y, wherein A and A? are each polypeptides capable of binding a target receptor. The fusion polypeptides of the invention form multimeric proteins which activate the target receptor. A and A? may be each be an antibody or fragment derived from an antibody specific for a target receptor, such as the same or different scFv fragments, and/or a ligand or ligand fragment or derivative capable of binding the target protein, M is a multimerizing component, and X and Y are independently a number between 1-10.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: December 3, 2013
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: James P. Fandl, Gang Chen, Nicholas J. Papadopoulos, Thomas H. Aldrich
  • BISPECIFIC ANTIBODIES AND METHODS OF USING THE SAME
    Publication number: 20130315911
    Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
    Type: Application
    Filed: May 21, 2013
    Publication date: November 28, 2013
    Applicant: Bristol-Myers Squibb Company
    Inventors: Brenda L. Stevens, Alison Witte, Mark W. Rixon, Josephine M. Cardarelli, Thomas D. Kempe, Scott R. Presnell, Mohan Srinivasan, Susan C. Wong, Guodong Chen, Hui Wei, Stanley R. Krystek, Lumelle A. Schneeweis, Paul O. Sheppard, Indrani Chakraborty
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
    Publication number: 20130315910
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: November 29, 2012
    Publication date: November 28, 2013
    Applicant: XENCOR, INC.
    Inventor: Xencor, Inc.
  • Inhibition of TACE or amphiregulin for the modulation of EGF receptor signal transactivation
    Patent number: 8591903
    Abstract: The present invention relates to the modulation of transactivation of receptor tyrosine kinases by G protein or G protein-coupled receptor (GPCR) mediated signal transduction in a cell or an organism comprising inhibiting the activity of the metalloprotease TACE/ADAM17 and/or the activity of the receptor tyrosine kinase ligand amphiregulin.
    Type: Grant
    Filed: March 9, 2009
    Date of Patent: November 26, 2013
    Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Axel Ullrich, Andreas Gschwind, Stefan Hart
  • Chemokine receptor binding polypeptides
    Patent number: 8591896
    Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.
    Type: Grant
    Filed: November 7, 2011
    Date of Patent: November 26, 2013
    Assignee: Novartis AG
    Inventors: Michelle Bradley, Zarin Brown, Steven John Charlton, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Gino Van Heeke
  • CORRELATION OF DE NOVO-INDUCED TUMOR-ASSOCIATED HUMORAL IMMUNE RESPONSES WITH IMPROVED CLINICAL OUTCOME
    Publication number: 20130309234
    Abstract: The present invention refers to a method for predicting an improved therapeutic benefit for an individual suffering from a tumor carrying a known tumor-associated cell surface antigen (such as EpCAM). The present invention further refers to a method for the induction of secondary humoral immune responses directed against a second tumor-associated antigen (e.g., another tumor-associated antigen, like HER2/neu) different from the first tumor-associated antigen in an individual suffering from a tumor comprising tumor cells expressing the first tumor-associated antigen, e.g., EpCAM.
    Type: Application
    Filed: March 14, 2013
    Publication date: November 21, 2013
    Inventor: Horst Lindhofer
  • ANTI-INTERFERON-ALPHA ANTIBODIES
    Publication number: 20130309236
    Abstract: The present invention relates generally to the generation and characterization of neutralizing anti-IFN-? monoclonal antibodies with broad reactivity against various IFN-? subtypes. The invention further relates to the use of such anti-IFN-? antibodies in the diagnosis and treatment of disorders associated with increased expression of TUN-?, in particular, autoimmune disorders such as insulin-dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE).
    Type: Application
    Filed: July 31, 2013
    Publication date: November 21, 2013
    Applicant: Genentech, Inc.
    Inventors: Anan CHUNTHARAPAI, Jin K. Kim, Leonard G. Presta, Timothy Stewart
  • ANTAGONISTS OF IL-17A, IL-17F, AND IL-23P19
    Publication number: 20130309235
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
    Type: Application
    Filed: June 27, 2013
    Publication date: November 21, 2013
    Applicant: ZymoGenetics, Inc.
    Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
  • Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
    Patent number: 8586041
    Abstract: Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Grant
    Filed: May 11, 2009
    Date of Patent: November 19, 2013
    Assignee: Genmab A/S
    Inventors: Jan G. J. van de Winkel, Marcus Antonius van Dijk, Edward Halk, Arnout F. Gerritsen, Jorgen Petersen, Ole Baadsgaard
  • Degraded TPO agonist antibody
    Patent number: 8586039
    Abstract: The invention relates to a modified antibody which contains two or more H chain V regions and two or more L chain V regions of monoclonal antibody and can transduce a signal into cells by crosslinking TPO receptor to thereby exert TPO agonist action. The modified antibody can be used as a TPO signal transduction agonist and, therefore, useful as a remedy for various diseases such as platelet-reduction-related blood diseases, thrombopenia following chemotherapy for cancer or leukemia, etc.
    Type: Grant
    Filed: September 6, 2011
    Date of Patent: November 19, 2013
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Masayuki Tsuchiya, Toshihiko Ohtomo, Naohiro Yabuta, Hiroyuki Tsunoda, Tetsuro Orita
  • DISULFIDE STABILIZED DVD-IG MOLECULES
    Publication number: 20130302336
    Abstract: A re-epoxidized polyfunctional epoxy resin composition comprising the reaction product of: (I) an epoxidized polyfunctional epoxy resin oligomeric composition comprising a polyfunctional aliphatic or cycloaliphatic epoxy resin which has been isolated from an epoxy resin product formed as a result of an epoxidation process comprising the reaction of: (i) an aliphatic or cycloaliphatic hydroxyl-containing material; (ii) an epihalohydrin, (iii) a basic-acting substance, in the presence of (iv) a non-Lewis acid catalyst; and (v) optionally, one or more solvents; (II) an epihalohydrin; (III) a basic acting substance; in the presence of (IV) a non-Lewis acid catalyst; and (V) optionally, one or more solvents. A curable epoxy resin composition of the re-epoxidized polyfunctional epoxy resin composition and a thermoset of the curable composition is also disclosed.
    Type: Application
    Filed: March 25, 2011
    Publication date: November 14, 2013
    Applicant: UCB PHARMA S.A.
    Inventors: Sam Philip Heywood, David Paul Humphreys
  • Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
    Patent number: 8580263
    Abstract: Anti-EGFR family member antibodies and bispecific antibodies comprising one or more anti-EGFR family member antibodies are disclosed. These antibodies can be used to advantage to specifically target forms of cancer associated with the overexpression of members of the EGFR protein family.
    Type: Grant
    Filed: November 20, 2007
    Date of Patent: November 12, 2013
    Assignees: The Regents of the University of California, Fox Chase Cancer Center
    Inventors: Gregory P. Adams, Eva M. Horak, Louis M. Weiner, James D. Marks
  • MONOCLONAL ANTIBODIES TARGETING AMYLOID BETA OLIGOMERS
    Publication number: 20130295095
    Abstract: The invention relates to binding molecules capable of specifically recognizing soluble oligomers of N-terminal truncated A? starting with pyroglutamate (A??E), pharmaceutical compositions comprising same, and their respective therapeutic uses. Particularly, the invention relates to an antibody molecule capable of specifically recognizing A? oligomers, wherein said antibody binds and/or detects an epitope as bound and/or detected by antibody PG3-38 9D5H6 as deposited under DSM AC-C3056.
    Type: Application
    Filed: June 3, 2011
    Publication date: November 7, 2013
    Inventors: Thomas Bayer, Oliver Wirths, Henrik Martens, Christian Erck
  • MULTISPECIFIC EPITOPE BINDING PROTEINS AND USES THEREOF
    Publication number: 20130295098
    Abstract: The present invention relates to multispecific epitope binding proteins, methods of making, and uses thereof in the prevention, management, treatment or diagnosis of acute or chronic diseases.
    Type: Application
    Filed: July 5, 2013
    Publication date: November 7, 2013
    Inventors: Herren Wu, Changshou Gao, Carl Hay, Nazzareno Dimasi
  • DEGRADED AGONIST ANTIBODY
    Publication number: 20130295096
    Abstract: The invention relates to a modified antibody which contains two or more H chain V regions and two or more L chain V regions of monoclonal antibody and can transduce a signal into cells by crosslinking a cell surface molecule(s) to thereby serve as an agonist.
    Type: Application
    Filed: April 3, 2013
    Publication date: November 7, 2013
    Inventors: Naoshi Fukushima, Masayuki Tsuchiya, Shinsuke Uno, Toshihiko Ohtomo, Naohiro Yabuta, Hiroyuki Tsunoda
  • Human Antibodies to Fel d1 and Methods of Use Thereof
    Publication number: 20130295097
    Abstract: The present invention provides antibodies that bind to the cat allergen, Fel d1, compositions comprising the antibodies, nucleic acids encoding the antibodies and methods of use of the antibodies. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Fel d1. The antibodies of the invention are useful for binding to the Fel d1 allergen in vivo, thus preventing binding of the Fel d1 allergen to pre-formed IgE on the surface of mast cells or basophils. In doing so, the antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and/or basophils, thus ameliorating the untoward response to the cat allergen in sensitized individuals. The antibodies of the invention may also be useful for diagnostic purposes to determine if a patient is allergic to the Fel d1 cat allergen.
    Type: Application
    Filed: May 2, 2013
    Publication date: November 7, 2013
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Jamie Orengo, Andrew J. Murphy
  • VEGF antibodies comprising modular recognition domains
    Patent number: 8574577
    Abstract: Antibodies containing one or more modular recognition domains (MRDs) that can be used to target the antibodies to specific sites are described. The use of antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also described.
    Type: Grant
    Filed: July 14, 2011
    Date of Patent: November 5, 2013
    Assignee: The Scripps Research Institute
    Inventor: Carlos F. Barbas, III
  • Monoclonal antibodies that recognize neurospheres or neural progenitor cells
    Patent number: 8574580
    Abstract: Method for generating monoclonal antibodies that recognize progenitor cells. Said method comprises immunization of an Armenian hamster with neurospheres obtained from olfactory bulb cells from a 13.5-day mouse embryo and subsequent selection of the antibodies by means of neurosphere flow cytometry in the presence of propidium iodide. The antibodies thus obtained may be of use in the enrichment of cell cultures in progenitor cells, primarily neural progenitor cells.
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: November 5, 2013
    Assignee: Consejo Superior de Investigaciones Científicas
    Inventors: Augusto Silva Gonzalez, Ignacio Del Valle Torres, Leyre García Benzaquen
  • HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME
    Publication number: 20130287779
    Abstract: The present invention concerns antibodies to EGFL7 and the uses of same.
    Type: Application
    Filed: June 17, 2013
    Publication date: October 31, 2013
    Inventors: Weilan YE, Mark S. Dennis, Jill Fredrickson
  • ANTI-HER3 ANTIBODIES AND COMPOSITIONS
    Publication number: 20130287684
    Abstract: The present invention relates to novel therapeutic recombinant antibodies directed against HER3 (ErbB3), as well as compositions comprising mixtures of at least two of said recombinant anti-HER3 antibodies, and use of the antibodies and antibody compositions for treatment of cancer.
    Type: Application
    Filed: October 31, 2011
    Publication date: October 31, 2013
    Applicant: SYMPHOGEN A/S
    Inventors: Mikkel Wandahl Pedersen, Helle Jacobsen, Klaus Koefoed
  • COMBINATION THERAPY FOR TREATMENT OF IMMUNE DISORDERS
    Publication number: 20130287775
    Abstract: Methods and compositions are provided for the treatment of immune disorders, such as autoimmune diseases, or cancers, involving combination therapy with agents that inhibit the development or maintenance of Th17 cells. Treatment regimens are provided in which an antagonist of a pro-inflammatory cytokine is administered for a time sufficient to alleviate signs and symptoms of an acute phase flare-up of the autoimmune disease, or cancer, and treatment with an antagonist of IL-23 is continued for a longer time to prevent recurrence of the acute event. Antagonists of PGE2 and CD161 are also disclosed for use in treatment of autoimmune, inflammatory and proliferative disorders.
    Type: Application
    Filed: June 24, 2013
    Publication date: October 31, 2013
    Inventors: Edward P. Bowman, Daniel J. Cua, Robert A. Kastelein, Kathy L. Miller, Melanie A. Kleinschek, Kristian S. Bak-Jensen, Katia Boniface, Brent S. McKenzie, Rene de Waal Malefyt
  • MEANS AND METHODS FOR TREATING DLBCL
    Publication number: 20130287778
    Abstract: The present invention provides means and methods for treating diffuse large B cell lymphoma (DLBCL). Specifically, a bispecific CD19×CD3 antibody which engages T cells via its CD3 binding portion and concomitantly binds to CD19 on the surface of in particular, lymphoma cells via its CD19 binding portion (i.e. a bispecific T cell engager, “BiTE”) is administered for use in the treatment of tumorous mass of lymophoreticular tissue and/or extranodal lymphoma caused by DLBCL in a patient.
    Type: Application
    Filed: October 27, 2011
    Publication date: October 31, 2013
    Applicant: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Gerhard Zugmaier, Dirk Nagorsen, Juergen Scheele
  • ANTI-FGFR3 ANTIBODIES AND METHODS USING SAME
    Publication number: 20130287776
    Abstract: The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Application
    Filed: February 7, 2013
    Publication date: October 31, 2013
    Applicant: GENENTECH, INC.
    Inventor: Genentech, Inc.
  • ST2L Antagonists and Methods of Use
    Publication number: 20130287777
    Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
    Type: Application
    Filed: March 13, 2013
    Publication date: October 31, 2013
    Applicant: JANSSEN BIOTECH, INC.
    Inventors: Karen Duffy, Natalie Fursov, LeRoy Hall, Catherine Healy, Roberta Lamb, Jinquan Luo, Ravi Malaviya, Michael Naso, Michael Pratta, Mark Tornetta, John Wheeler, Sheng-Jiu Wu
  • PRODUCTS AND METHODS TO PREVENT INFECTIONS
    Publication number: 20130287780
    Abstract: The present invention relates to products and methods for preventing, ameliorating and/or treating infections and other diseases. In one aspect, the products of the present invention relates to compositions comprising germ free colostrum. In another aspect, the products of the present invention relates to compositions comprising synthetically multimerised immunoglobulins. In a third aspect, the products of the present invention relates to compositions comprising germ free colostrum enriched with synthetically multimerised immunoglobulins. The invention also relates to use of said compostions as a pharmaceutical e.g. for prophylactic or ameliorating treatment of infections and other diseases. In addition the invention comprises methods for production of said compositions.
    Type: Application
    Filed: June 28, 2013
    Publication date: October 31, 2013
    Inventor: Kirsten BISGAARD-FRANTZEN
  • IL-1 BINDING PROTEINS
    Publication number: 20130280253
    Abstract: The present invention encompasses IL-1? binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Antibodies of the invention have high affinity for IL-1? and neutralize IL-1? activity. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting IL-1? and for inhibiting IL-1? activity, e.g., in a human subject suffering from a disorder in which IL-1? activity is detrimental.
    Type: Application
    Filed: February 6, 2013
    Publication date: October 24, 2013
    Inventors: Chung-ming Hsieh, Chengbin Wu
  • ANTI-BAFF-ANTI-IL-17 BISPECIFIC ANTIBODIES
    Publication number: 20130280256
    Abstract: Bispecific antibodies are provided that specifically bind B-cell Activating Factor of the TNF Family (BAFF) and Interleukin-17A (IL-17) and are characterized as having high affinity and strong neutralizing properties to both BAFF and IL-17. The bispecific antibodies of the invention are expected to be useful in treating Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Psoriasis (Ps), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PA), primary Sjögren's Syndrome (pSS), or Multiple Myeloma (MM).
    Type: Application
    Filed: April 16, 2013
    Publication date: October 24, 2013
    Applicant: Eli Lilly and Company
    Inventors: Barrett Allan, Robert Jan Benschop, Jirong Lu
  • THERAPIES FOR IMPROVING PULMONARY FUNCTION
    Publication number: 20130281876
    Abstract: The disclosure relates to IL-13 antagonists, in particular anti-human-IL-13 antibodies and human-IL-13-binding fragments thereof, and their use for improvement, maintenance or reduction in the rate of decline of pulmonary function in a subject with impaired pulmonary function, which may be associated with uncontrolled moderate-to-asthma, COPD or IPF.
    Type: Application
    Filed: October 14, 2011
    Publication date: October 24, 2013
    Applicant: MEDIMMUNE LIMITED
    Inventors: Raffaella Faggioni, Richard May, Chris Kell, Nester Molfino, Lorin Roskos
  • AGENTS AND METHODS FOR TREATING DISEASES THAT CORRELATE WITH BCMA EXPRESSION
    Publication number: 20130273055
    Abstract: A bispecific binding agent comprising at least two binding domains, wherein a first binding domain binds to the B cell maturation antigen BCMA and wherein a second binding domain binds to CD3, pharmaceutical compositions containing such agent and use for the treatment of plasma cell disorders or B cell disorders which correlate with BCMA expression.
    Type: Application
    Filed: November 16, 2011
    Publication date: October 17, 2013
    Inventors: Eric Borges, Jasmin Barbara Hebeis
  • Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
    Publication number: 20130273053
    Abstract: In one aspect, the invention provides methods and compositions for inhibiting MASP-3-dependent complement activation in a subject suffering from paroxysmal nocturnal hemoglobinuria by administering to the subject a composition comprising an amount of a MASP-3 inhibitory agent in an amount effective to inhibit MASP-3-dependent complement activation. In another aspect, the invention provides methods and compositions for increasing the survival of red blood cells in a subject suffering from paroxysmal nocturnal hemoglobinuria by administering to the subject a composition comprising an amount of at least one of a MASP-1 inhibitory agent and/or a MASP-3 inhibitory agent effective to increase the survival of red blood cells.
    Type: Application
    Filed: April 5, 2013
    Publication date: October 17, 2013
    Applicants: UNIVERSITY OF LEICESTER, OMEROS CORPORATION
    Inventors: OMEROS CORPORATION, UNIVERSITY OF LEICESTER
  • Bispecific Anti ErbB2/Anti cMet Antibodies
    Publication number: 20130273054
    Abstract: The present invention relates to bispecific antibodies against human ErbB-2 and against human C-met, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.
    Type: Application
    Filed: April 10, 2013
    Publication date: October 17, 2013
    Applicant: ROCHE GLYCART AG
    Inventor: ROCHE GLYCART AG
  • ACTIVATABLE BISPECIFIC ANTIBODIES
    Publication number: 20130266568
    Abstract: The current invention relates to bispecific antibodies wherein the binding affinity to one of the two antigens is reduced and which can be activated by tumor- or inflammation-specific proteases, and the preparation and use of such bispecific antibodies.
    Type: Application
    Filed: February 21, 2013
    Publication date: October 10, 2013
    Inventors: ULRICH BRINKMANN, REBECCA CROASDALE, SILKE METZ, JUERGEN MICHAEL SCHANZER, CLAUDIO SUSTMANN, PABLO UMANA
  • THREE-DIMENSIONAL STRUCTURE OF COMPLEMENT RECEPTOR TYPE 2 AND USES THEREOF
    Publication number: 20130266571
    Abstract: Disclosed is a crystalline human CR2 protein in complex with C3d, and the three dimensional structure of the crystalline complex. Also disclosed are methods of use of the structure, particularly for structure-based identification of compounds that bind to CR2 and inhibit or enhance the binding of CR2 to a natural ligand, that bind to CR2 and agonize or antagonize the receptor, that bind to CR2 and inhibit or enhance CR2 dimerization, or that use the C3-binding ability of CR2 as a drug delivery vehicle. Also disclosed are therapeutic compounds obtained by such methods and uses for such compounds.
    Type: Application
    Filed: June 13, 2013
    Publication date: October 10, 2013
    Inventors: Xiaojiang CHEN, V. Michael Holers
  • COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER
    Publication number: 20130266569
    Abstract: An isolated antibody that specifically binds to an extracellular domain of human DLL4 and affects growth of a tumor comprising cancer stem cells is described. Also described is a method of treating cancer comprising administering a therapeutically effective amount of an anti-DLL4 antibody.
    Type: Application
    Filed: March 14, 2013
    Publication date: October 10, 2013
    Inventors: Austin L. GURNEY, Fumiko Takada Axelrod, Timothy Charles Hoey, Sanjeev H. Satyal
  • Targeting Intracellular Target-binding Determinants with Intracellular Antibodies
    Publication number: 20130266570
    Abstract: The invention provides a method for inhibiting an intracellular target in a cell with a bispecific antibody comprising contacting the cell with a bispecific antibody having a first Fv fragment with a cell-penetrating determinant and a second Fv fragment with an intracellular target-binding determinant under suitable conditions so that the first Fv fragment causes the bispecific antibody to enter the cell and the second Fv fragment binds the intracellular target in the cell and thereby inhibiting the intracellular target.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 10, 2013
    Inventors: Richard H. Weisbart, Robert N. Nishimura
  • ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES
    Publication number: 20130259866
    Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.
    Type: Application
    Filed: March 11, 2013
    Publication date: October 3, 2013
    Applicant: SANOFI
    Inventors: Ercole RAO, Vincent MIKOL, Danxi LI, Jochen KRUIP, Matthew DAVISON
  • DIAGNOSIS AND TREATMENTS RELATING TO HER3 INHIBITORS
    Publication number: 20130259867
    Abstract: The present application describes the use of NRG1 overexpression as a selection criterion for treating cancer patients with a HER3 inhibitor, such as a bispecific HER3/EGFR inhibitor, and methods of treating those patients.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 3, 2013
    Applicant: GENENTECH, INC.
    Inventors: Lukas Amler, David Shames
  • Ang-2 Binding Complexes and Uses Thereof
    Publication number: 20130259868
    Abstract: Complexes containing one or more modular recognition domains (MRDs) and MRDs attached to scaffold's including antibodies are described. The manufacture of these complexes are the use of these complexes to treat and diagnose diseases and disorders are also described.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 3, 2013
    Inventors: Viktor ROSCHKE, David Lafleur, David M. Hilbert, Peter Kiener
  • ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES
    Publication number: 20130251718
    Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.
    Type: Application
    Filed: March 11, 2013
    Publication date: September 26, 2013
    Applicant: SANOFI
    Inventors: Ercole RAO, Vincent MIKOL, Danxi LI, Jochen KRUIP, Matthew DAVISON
  • ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES
    Publication number: 20130251717
    Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.
    Type: Application
    Filed: March 11, 2013
    Publication date: September 26, 2013
    Applicant: SANOFI
    Inventors: Ercole RAO, Vincent MIKOL, Danxi LI, Jochen KRUIP, Matthew DAVISON
  • ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES
    Publication number: 20130251716
    Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.
    Type: Application
    Filed: March 11, 2013
    Publication date: September 26, 2013
    Applicant: Sanofi
    Inventors: Ercole RAO, Vincent MIKOL, Danxi LI, Jochen KRUIP, Matthew DAVISON
  • TARGETED ENZYMATIC DEGRADATION OF QUORUM-SENSING PEPTIDES
    Publication number: 20130253382
    Abstract: Methods and compositions for the treatment of biofilms and/or the inhibition of biofilm formation. In one embodiment, a biofilm is treated and/or biofilm formation is inhibited by a method comprising contacting a biofilm or a surface with a bifunctional ligand comprising a quorum-sensing-peptide-binding region and a protease-binding region, whereby the biofilm is treated and/or biofilm formation on the surface is inhibited.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 26, 2013
    Inventors: RODOLFO ALARCON, Amy K. McNulty
  • NOTCH1 BINDING AGENTS AND METHODS OF USE THEREOF
    Publication number: 20130243774
    Abstract: The present invention relates to Notch1 binding agents and methods of using the agents for treating diseases, such as hematologic cancers. The present invention provides antibodies that specifically bind to a non-ligand binding membrane proximal region of the extracellular domain of human Notch1. The present invention further provides methods of using agents that inhibit Notch1 activity for treating cancer. Also described are methods of treating hematologic cancers comprising administering a therapeutically effective amount of a binding agent or antibody of the present invention to a subject having a hematologic cancer such as T-cell lymphoblastic leukemia.
    Type: Application
    Filed: March 12, 2013
    Publication date: September 19, 2013
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Edward Thein Htun van der HORST, Austin L. GURNEY, Timothy Charles HOEY, Maureen Fitch BRUHNS, Fumiko Takada AXELROD
  • RECOMBINANT PRODUCTION OF MIXTURES OF ANTIBODIES
    Publication number: 20130243773
    Abstract: Provided is methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields.
    Type: Application
    Filed: March 12, 2013
    Publication date: September 19, 2013
    Applicant: Merus B.V.
    Inventors: Patricius Hendrikus Van Berkel, Ronald Hendrik Peter Brus, Ton Logtenberg, Abraham Bout
  • ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN OX40
    Publication number: 20130243772
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: November 8, 2012
    Publication date: September 19, 2013
    Applicant: UCB Pharma S.A.
    Inventors: Ralph Adams, Pallavi Bhatta, Sam Phillip Heywood, David Paul Humphreys
  • ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES
    Publication number: 20130243777
    Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 19, 2013
    Applicant: Sanofi
    Inventors: Ercole RAO, Vincent MIKOL, Danxi LI, Jochen KRUIP, Matthew DAVISON